Avisi is a medical devices startup investigating the use of patented nanotechnology in an ocular implant to stop blindness in glaucoma patients.
Glaucoma is the second leading cause of blindness in the world and currently has no cure.
To date, Avisi has been supported by grants and awards from: the National Science Foundation, Ben Franklin Technology Partners, the University of Pennsylvania, Wharton, The School of Engineering and Applied Science, Venture Initiation Program Accelerator (VIP-X), Penn Law’s Entrepreneurship Legal Clinic, VentureWell E-Teams, and Ballard Spahr BASE.
Avisi is a proud member of Johnson & Johnson JLABS incubator, UCSF Rosenman Innovators, OC OCTANE LaunchPad, and MedTech Innovator Accelerator.
Twitter: @avisi_tech
Website: www.avisitech.com
Company’s Keywords:
glaucoma & nanotechnology
<11
<
<2017